Cyclooxygenase-2 Genetic Variants Are Predictive of Patient Benefit: Biomarker Analyses from a Randomized Phase II Trial Evaluating Concurrent Chemoradiotherapy with or Without Celecoxib in Unresectable Stage III Non-Small Cell Lung Cancer | |
Bi, N.; Liang, J.; Zhou, Z.; Chen, D.; Fu, Z.; Yang, X.; Hui, Z.; Feng, Q.; Xiao, Z.; Lv, J. | |
2018 | |
会议名称 | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS |
会议日期 | 2018-11-01 |
页码 | S16-S17 |
收录类别 | CPCI-S |
URL标识 | 查看原文 |
内容类型 | 会议论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/6351460 |
专题 | 中国医学科学院 北京协和医学院 |
推荐引用方式 GB/T 7714 | Bi, N.,Liang, J.,Zhou, Z.,et al. Cyclooxygenase-2 Genetic Variants Are Predictive of Patient Benefit: Biomarker Analyses from a Randomized Phase II Trial Evaluating Concurrent Chemoradiotherapy with or Without Celecoxib in Unresectable Stage III Non-Small Cell Lung Cancer[C]. 见:INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2018-11-01. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论